Literature DB >> 19377487

The parametric response map is an imaging biomarker for early cancer treatment outcome.

Craig J Galbán1, Thomas L Chenevert, Charles R Meyer, Christina Tsien, Theodore S Lawrence, Daniel A Hamstra, Larry Junck, Pia C Sundgren, Timothy D Johnson, David J Ross, Alnawaz Rehemtulla, Brian D Ross.   

Abstract

Here we describe the parametric response map (PRM), a voxel-wise approach for image analysis and quantification of hemodynamic alterations during treatment for 44 patients with high-grade glioma. Relative cerebral blood volume (rCBV) and flow (rCBF) maps were acquired before treatment and after 1 and 3 weeks of therapy. We compared the standard approach using region-of-interest analysis for change in rCBV or rCBF to the change in perfusion parameters on the basis of PRM (PRM(rCBV) and PRM(rCBF)) for their accuracy in predicting overall survival. Neither the percentage change of rCBV or rCBF predicted survival, whereas the regional response evaluations made on the basis of PRM were highly predictive of survival. Even when accounting for baseline rCBV, which is prognostic, PRM(rCBV) proved more predictive of overall survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377487      PMCID: PMC3307223          DOI: 10.1038/nm.1919

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  32 in total

Review 1.  Model-based and model-free parametric analysis of breast dynamic-contrast-enhanced MRI.

Authors:  Erez Eyal; Hadassa Degani
Journal:  NMR Biomed       Date:  2009-01       Impact factor: 4.044

2.  Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.

Authors:  Susan M Galbraith; Martin A Lodge; N Jane Taylor; Gordon J S Rustin; Søren Bentzen; J James Stirling; Anwar R Padhani
Journal:  NMR Biomed       Date:  2002-04       Impact factor: 4.044

3.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

4.  Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

Authors:  Bruno Morgan; Anne L Thomas; Joachim Drevs; Juergen Hennig; Martin Buchert; Asvina Jivan; Mark A Horsfield; Klaus Mross; Howard A Ball; Lucy Lee; William Mietlowski; Stefan Fuxuis; Clemens Unger; Ken O'Byrne; Andrew Henry; Graham R Cherryman; Dirk Laurent; Margaret Dugan; Dieter Marmé; William P Steward
Journal:  J Clin Oncol       Date:  2003-09-29       Impact factor: 44.544

5.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Meng Law; Robert J Young; James S Babb; Nicole Peccerelli; Sophie Chheang; Michael L Gruber; Douglas C Miller; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  Radiology       Date:  2008-03-18       Impact factor: 11.105

6.  Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas.

Authors:  Robert Young; James Babb; Meng Law; Erica Pollack; Glyn Johnson
Journal:  J Magn Reson Imaging       Date:  2007-10       Impact factor: 4.813

7.  Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series.

Authors:  Gunnar Brix; Fabian Kiessling; Robert Lucht; Susanne Darai; Klaus Wasser; Stefan Delorme; Jürgen Griebel
Journal:  Magn Reson Med       Date:  2004-08       Impact factor: 4.668

8.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.

Authors:  Kuei C Lee; Sudha Sud; Charles R Meyer; Bradford A Moffat; Thomas L Chenevert; Alnawaz Rehemtulla; Kenneth J Pienta; Brian D Ross
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

9.  Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas.

Authors:  M Law; R Young; J Babb; E Pollack; G Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

10.  A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.

Authors:  Kuei C Lee; Deborah A Bradley; Maha Hussain; Charles R Meyer; Thomas L Chenevert; Jon A Jacobson; Timothy D Johnson; Craig J Galban; Alnawaz Rehemtulla; Kenneth J Pienta; Brian D Ross
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

View more
  95 in total

Review 1.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Authors:  Anwar R Padhani; Aftab Alam Khan
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

Review 2.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

Review 3.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

Review 4.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

5.  Image registration for quantitative parametric response mapping of cancer treatment response.

Authors:  Jennifer L Boes; Benjamin A Hoff; Nola Hylton; Martin D Pickles; Lindsay W Turnbull; Anne F Schott; Alnawaz Rehemtulla; Ryan Chamberlain; Benjamin Lemasson; Thomas L Chenevert; Craig J Galbán; Charles R Meyer; Brian D Ross
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

6.  Physiological imaging-defined, response-driven subvolumes of a tumor.

Authors:  Reza Farjam; Christina I Tsien; Felix Y Feng; Diana Gomez-Hassan; James A Hayman; Theodore S Lawrence; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-17       Impact factor: 7.038

7.  Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources.

Authors:  Charles R Meyer; Samuel G Armato; Charles P Fenimore; Geoffrey McLennan; Luc M Bidaut; Daniel P Barboriak; Marios A Gavrielides; Edward F Jackson; Michael F McNitt-Gray; Paul E Kinahan; Nicholas Petrick; Binsheng Zhao
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

8.  Diffusion imaging for therapy response assessment of brain tumor.

Authors:  Thomas L Chenevert; Brian D Ross
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

Review 9.  Clinical applications for diffusion magnetic resonance imaging in radiotherapy.

Authors:  Christina Tsien; Yue Cao; Thomas Chenevert
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

10.  The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.

Authors:  Pierre Starkov; Todd A Aguilera; Daniel I Golden; David B Shultz; Nicholas Trakul; Peter G Maxim; Quynh-Thu Le; Billy W Loo; Maximillan Diehn; Adrien Depeursinge; Daniel L Rubin
Journal:  Br J Radiol       Date:  2018-11-20       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.